Roche's MabThera receives EU approval for the most common type of leukaemia
This article was originally published in Scrip
Roche's monoclonal antibody drug MabThera (rituximab) has received an EU marketing approval as a first line treatment for chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.